Janssen Reports Five-Year Data of Stelara (ustekinumab) in P-lll LTE Study for Severe Crohn’s Disease

 Janssen Reports Five-Year Data of Stelara (ustekinumab) in P-lll LTE Study for Severe Crohn’s Disease

Janssen Pharmaceutical Reports Five-Year of Stelara (ustekinumab) in P-lll LTE Study for Severe Crohn’s Disease

Shots:

  • The P-lll IM-UNITI LTE study involves assessing of Stelara (SC, 90mg, q8w/q12w) vs PBO as maintenance therapy in 1,281 patients with moderate to severe CD. All patients completing 44wks. were eligible to enter the LTE program, continuing their current regimen ~252wks.
  • 50%+ patients were randomized to q8w dosing and continued to receive this dosage in the LTE study, maintained CR (57%) and remission (55 %) through 5 yrs. of treatment while (93%) were steroid-free. Among patients who had prior exposure to & failed to TNF-α biologics, clinical remission (59% & 44%) respectively
  • Stelara is a fully human mAb & is the first and only biologic treatment to selectively inhibit the (IL)-12 and IL-23 pathways and is approved in the US for multiple diseases

    Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: WebMD

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post